By Fineline Cube 
US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced an ongoing collaboration between its unit Cytiva and Shanghai-based gene editing technology provider CorrectSequence Therapeutics. Together, they are developing an innovative process solution for gene therapy using lipid nanoparticle (LNP) delivery systems. This partnership aims to drive breakthroughs in treating genetic diseases and marks Danaher’s first Beacon Project with a Chinese biotech firm.
Cytiva’s Fast Trak Center
Cytiva’s Fast Trak center in Shanghai’s Zhangjiang area is pivotal to this collaboration. It provides core technical support, including process development and scalable manufacturing for gene editing therapies. The center is home to Asia’s largest modular bioprocessing workstation and offers comprehensive services from nucleic acid drug preparation to cGMP-scale production.
Proven Track Record
The Fast Trak center has successfully completed numerous gene therapy process development projects. Its expertise and state-of-the-art facilities are key to advancing the development of gene therapies, which hold great promise for treating genetic diseases.-Fineline Info & Tech